The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
The ESMO Tumour-Agnostic Classifier (ETAC) focuses on the interplay of targeted driver molecular aberration and tumour-specific biology modulating the therapeutic effect of MGTOs. We propose minimum requirements to screen for tumour-agnostic potential (ETAC-S) as part of tumour-agnostic drug development. Definition of ETAC cut-offs is warranted.
Authors
- Fabrice André (ORCID: https://orcid.org/0000-0001-5795-8357)
- Diogo Martins-Branco (ORCID: https://orcid.org/0000-0002-7214-4818)
- Shivaani Kummar (ORCID: https://orcid.org/0000-0001-6906-1627)
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Claudia Cardone (ORCID: https://orcid.org/0000-0003-4502-1932)
- George E. Pentheroudakis (ORCID: https://orcid.org/0000-0002-6632-2462)
- Sonja Loges (ORCID: https://orcid.org/0000-0002-7650-8527)
- Christina Gertrude Yap (ORCID: https://orcid.org/0000-0002-6715-2514)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Joaquı́n Mateo (ORCID: https://orcid.org/0000-0001-5336-2548)
- Juliana Rodrigues Beal (ORCID: https://orcid.org/0000-0001-8898-0549)
- Vivek Subbiah (ORCID: https://orcid.org/0000-0002-6064-6837)
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Susan Halabi (ORCID: https://orcid.org/0000-0003-4135-2777)
- C. Benedikt Westphalen (ORCID: https://orcid.org/0000-0002-5310-3754)
- Elena Garralda (ORCID: https://orcid.org/0000-0002-4412-7842)
- Stefan Michiels (ORCID: https://orcid.org/0000-0002-6963-2968)
- N. Coleman
- Aurélien Marabelle (ORCID: https://orcid.org/0000-0002-5816-3019)
- Caterina Marchiò (ORCID: https://orcid.org/0000-0003-2024-6131)
- Frédéric Bibeau (ORCID: https://orcid.org/0000-0001-7126-1185)
- Sewanti Limaye (ORCID: https://orcid.org/0000-0001-6640-1470)
- Alison M. Schram (ORCID: https://orcid.org/0000-0002-6070-2413)
- Tanja Španič
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Institute of Cancer Research (GB)
- Inserm (FR)
- Oregon Health & Science University (US)
- Duke University (US)
- Université de Bourgogne (FR)
- German Cancer Research Center (DE)
- University of Milan (IT)
- Medical College of Wisconsin (US)
- Trinity College Dublin (IE)
- Cornell University (US)
- Heidelberg University (DE)
- Université Paris-Saclay (FR)
- Sir H.N. Reliance Foundation Hospital and Research Centre (IN)
- Alma Mater Europaea (SI)
- European Society for Medical Oncology (CH)
- Hospital Israelita Albert Einstein (BR)
- Institut Gustave Roussy (FR)
- University Hospital Heidelberg (DE)
- University Medical Center (US)
- Comprehensive Cancer Center Vienna (AT)
- La Ligue Contre le Cancer (FR)
- Sarah Cannon (US)
- Istituto Oncologico Veneto (IT)
- Vall d'Hebron Hospital Universitari (ES)
- German Center for Lung Research (DE)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Candiolo Cancer Institute (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- St. James's Hospital (IE)
- University Medical Centre Mannheim (DE)
- Vall d'Hebron Institute of Oncology (ES)
- Medical College of Wisconsin Cancer Center
- University of Turin (IT)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1016/j.annonc.2024.07.730
- Citations
- 45
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 16.26
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Alnylam Pharmaceuticals
- Regeneron Pharmaceuticals
- Incyte
- Syndax Pharmaceuticals
- Veracyte
- Actuate Therapeutics
- MacroGenics
- Seagen
- Eisai
- European Society for Medical Oncology
- Medac
- Grifols
- U.S. Food and Drug Administration
- Genentech
- Foundation Medicine
- National Cancer Institute
- Daiichi Sankyo Europe